跳至主要内容
临床试验/NCT02910089
NCT02910089已完成4 期

ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM): A 12-month Study of the Impact of Combined Shared-decision Making and Brief Negotiated Interviewing on Disease Control and Medication Adherence in Patients With Diabetes

AstraZeneca1 个研究点 分布在 1 个国家目标入组 1,400 人开始时间: 2016年10月20日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
发起方
AstraZeneca
入组人数
1,400
试验地点
1
主要终点
Glycosylated Hemoglobin (HbA1c):

研究概览

简要总结

The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with usual care. These engagement techniques include shared decision-making and brief negotiated interviewing and are delivered telephonically.

详细描述

The US is facing a growing epidemic of type 2 diabetes. Among patients with poorly controlled diabetes, it is often not clear whether the problem is attributable to failure to appropriately intensify therapy, poor adherence to prescribed medications, unwillingness to accept new treatments or a combination of these factors. Multi-component pharmacist-delivered interventions, particularly those rooted in patient engagement, have been shown to be some of the most effective at improving adherence to chronic disease medications. Even though shared decision making and brief negotiated interviewing are complementary patient engagement techniques, the effectiveness of combining these 2 intervention approaches, especially in the management of diabetes, is unknown.

In this study of patients using at least one oral hypoglycemic therapy with poorly controlled disease, the investigators examine the impact of a shared decision making and behavioral interviewing intervention delivered telephonically by pharmacists, compared with usual care. Briefly, all patients allocated to the intervention will be mailed a patient decision aid to prime them for encounters with pharmacists. After receiving the decision aid, these patients will be asked to engage in and provide informed consent for at least 4 telephonic discussions with pharmacists about their diabetes treatment options, goals, and preferences, medication adherence, strategies for reducing adherence barriers, and the benefits of maintaining blood glucose control. The study is being conducted within a large insurer and consists of 700 patients each allocated to the intervention group and the control group. Analyses will be performed on an intent-to-treat basis.

After study completion, the investigators will also use predictive analytics to examine whether treatment response could be predicted based on patient characteristics, such as sociodemographic, clinical, medication use, and other motivational characteristics, which will provide information about which patients are most likely to benefit from the intervention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 130 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Commercially-insured beneficiaries
  • Receive all medical/prescription drug benefits through Horizon
  • On ≥1 one oral hypoglycemic agent
  • Latest HbA1c measurement ≥ 8% (within previous 6 months)
  • Provided phone number to Horizon

排除标准

  • Currently using any insulin

研究组 & 干预措施

Shared Decision Making/Brief Negotiated Interviewing

Other

This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).

干预措施: Shared Decision Making (Behavioral)

Control Arm

No Intervention

Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.

结局指标

主要结局

Glycosylated Hemoglobin (HbA1c):

时间窗: baseline and at the end of 12 months post index date

Pre- to post-intervention change in mean HbA1c levels

次要结局

  • Medication Adherence (PDC Measure)(during follow-up period of 12 months post index date)
  • Percentage (Proportion x 100) of Patients Achieving Optimal Adherence(during follow-up period of 12 months post index date)
  • Patients Achieving HbA1c(baseline and at the end of 12 months post index date)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验